Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Current Assets (2020 - 2025)

Aligos Therapeutics filings provide 6 years of Current Assets readings, the most recent being $82.9 million for Q4 2025.

  • On a quarterly basis, Current Assets rose 33.35% to $82.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $82.9 million, a 33.35% increase, with the full-year FY2025 number at $82.9 million, up 33.35% from a year prior.
  • Current Assets hit $82.9 million in Q4 2025 for Aligos Therapeutics, down from $103.4 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $248.7 million in Q3 2021 to a low of $62.1 million in Q4 2024.
  • Median Current Assets over the past 5 years was $130.7 million (2022), compared with a mean of $137.6 million.
  • Biggest five-year swings in Current Assets: tumbled 55.95% in 2024 and later soared 33.35% in 2025.
  • Aligos Therapeutics' Current Assets stood at $204.4 million in 2021, then tumbled by 34.67% to $133.5 million in 2022, then increased by 5.65% to $141.1 million in 2023, then crashed by 55.95% to $62.1 million in 2024, then skyrocketed by 33.35% to $82.9 million in 2025.
  • The last three reported values for Current Assets were $82.9 million (Q4 2025), $103.4 million (Q3 2025), and $127.9 million (Q2 2025) per Business Quant data.